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A B S T R A C T
Background: Postoperative nausea and vomiting (PONV) is a distressing outcome related to surgeries.
Traditionally, ginger has been used in the treatment of nausea and vomiting for thousands of years. Recently,
several randomized, placebo-controlled clinical trials (RCTs) have been conducted to evaluate the eﬃcacy of
ginger in PONV.
Purpose: To systematically evaluate the eﬃcacy of ginger on postoperative nausea and vomiting (PONV) com-
pared to placebo, based on RCTs.
Study design: The meta-analysis was reported following the PRISMA guidelines using the PICO format, and it was
registered with the PROSPERO register.
Methods: PubMed, Embase, the Cochrane Central Register of Controlled Trials and Web of Science were searched
for relevant studies. Human, placebo-controlled clinical studies of patients undergoing any types of surgery,
receiving pharmacological doses of ginger per os were included. Only clinical trials with explicit description of
the ginger preparation used were analysed. No language or publication year restrictions was applied.
Results: Ten randomized trials including a total of 918 patients were pooled for the statistical analysis. The
present meta-analysis supports that ginger has a signiﬁcant eﬀect on the severity of PONV based on visual
analogue scale (VAS) results: in a ﬁxed eﬀects model the pooled standardized mean diﬀerence (SMD) was –0.247
(favouring ginger; [LL]: –0.455, [UL]: –0.040, p-value: 0.019). Moreover, our results suggest that ginger reduces
the incidence of postoperative nausea and vomiting, as well antiemetic drug demand; however, these eﬀects are
not statistically signiﬁcant compared to placebo, which may be explained by underdosing.
Conclusions: According to our thorough meta-analysis ginger is safe and well tolerated, and decreases the se-
verity of PONV, and may lower the incidence of postoperative nausea and vomiting, which in turn may reduce
antiemetic drug demand, suggesting that ginger may be a useful alternative to antiemetic medications to alle-
viate PONV.
Introduction
Postoperative nausea and vomiting (PONV) is one of the most
common complications in patients undergoing surgeries. In the post-
operative setting patients may ﬁnd PONV more distressing than post-
operative pain (ASPAN'S evidence-based clinical practice guideline for the
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prevention and/or management of PONV/PDNV, 2006). PONV can lead to
several secondary complications such as aspiration pneumonia, wound
disruption, gastric herniation, dehydration and fatigue; therefore, it can
elongate the time to recovery and increase care costs (Cao et al., 2017).
The incidence of PONV and the intensity of symptoms may vary de-
pending on several factors (Horn et al., 2014), including patient char-
acteristics (e.g. gender, age, previous history of PONV or motion sick-
ness) and surgical factors (e.g. type of surgery, length of anaesthesia,
use of postoperative opioids) (Gan et al., 2014).
PONV is triggered by several receptor systems, thus preventing and
treating PONV is a complex task. Dopamin (D2) antagonists (e.g. pro-
chlorperazine, metoclopramide), serotonin 5-HT3 antagonists (e.g. on-
dansetron, granisetron), anticholinergics (scopolamine), antihistamines
(H1 antagonists, e.g. dimenhydrinate) and neurokinin-1 (NK1) receptor
antagonists (aprepitant, rolapitant) are recommended to alleviate
PONV symptoms (Kovac, 2013). The use of these drugs is often limited
by their side eﬀects (e.g. in case of antihistamines, 5-HT3 antagonists)
or availability (NK-1 receptor antagonists) (Hu et al., 2015; Toyoda
et al., 2013; Fero et al., 2011). As the eﬀectiveness of an antiemetic
drug may be aﬀected by the patient's characteristics, there is no gold
standard for the treatment of PONV. Moreover, a modern antiemetic
drug with negligible side-eﬀects such as NK-1 receptor antagonists may
not be available or aﬀordable for all patients.
Ginger, an easily accessible plant in many Asian countries, has been
traditionally used in the treatment of gastrointestinal disorders since
ancient times (Sheikhi et al., 2015). Nowadays, it is still considered as
an alternative therapy for nausea and vomiting (Shariﬁ-Rad et al.,
2017). Ginger and its bioactive secondary metabolites, especially gin-
gerols and shogaols interact with the 5-HT3 signalling pathway
(Semwal et al., 2015). Moreover, ginger is reported to show antic-
holinergic and antihistaminergic activities in vitro, which may further
contribute to its antiemetic eﬀect (Abdel-Aziz et al., 2006; Pertz et al.,
2011).
According to the European Medicines Agency's HMPC monograph,
the use of ginger medicines containing 1–2 g of ginger per dose is based
on their ‘well-established use’ for the treatment of nausea and vomiting
in motion sickness (European Union herbal monograph on Zingiber oﬃ-
cinale Roscoe, rhizoma EMA/HMPC/296,580/2012, 2012). Ginger is
considered to be generally safe, but it should not be recommended for
pregnant women because of its in vitro mutagenic eﬀects (Srinivasan,
2017; Nagabhushan et al., 1987; Nakamura and Yamamoto 1983).
Upon consuming ginger medications, mild to moderate gastrointestinal
side eﬀects and sleepiness are reported to occur as the most common
adverse eﬀects (Assessment report on Zingiber oﬃcinale Roscoe, rhizoma
EMA/HMPC/577856/2010). No serious adverse events have not been
reported; therefore, the relative safety of ginger products could be a
major beneﬁt in therapy (Shariﬁ-Rad et al., 2017).
Recently, several RCTs have been conducted to evaluate the eﬀec-
tiveness of ginger in postoperative nausea and vomiting. The last sys-
tematic review on this topic was published more than twelve years ago
(Chaiyakunapruk et al., 2006). Therefore, the aim of the present meta-
analysis was to synthesize the published evidence, and evaluate the
antiemetic eﬃcacy of ginger in the postoperative setting.
Methods
The following PICO (patients, intervention, comparison, outcome)
format was applied: P: postoperative patients; I: pharmacological doses
of ginger given per os; C: placebo; and O: postoperative nausea and/or
vomiting. The meta-analysis was performed using the preferred re-
porting items for systematic review and meta-analysis protocols
(PRISMA-Protocol). The meta-analysis protocol was registered with the
Fig. 1. PRISMA 2009 ﬂow diagram for identiﬁcation of relevant studies.
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International Prospective Register of Systematic Reviews (PROSPERO)
on 21th April 2017 (registration number CRD42017064278).
Information sources and search strategy
Literature search was conducted until the 26th of February 2018, by
using the following search strategy: [(‘ginger’ /exp OR ginger) AND
nausea] for EMBASE; [(“ginger” [MeSH Terms] OR “ginger” [All
Fields]) AND (“nausea” [MeSH Terms] OR “nausea” [All Fields])] for
PubMed; ['ginger AND nausea in Title, Abstract, Keywords in Trials] for
Cochrane Central Register of Controlled Trials; and [TOPIC: (ginger
AND nausea) Timespan: All years. Indexes: SCI-EXPANDED, SSCI,
A&HCI, ESCI.] for Web of Science. To increase the hits of relevant
studies, the reference lists of all identiﬁed articles were inspected. No
language, publication date or publication status restrictions were used.
For the purpose of transparency, this meta-analysis was based on
publicly available data only, and neither the authors of included arti-
cles, nor the manufacturers of ginger products were contacted for ad-
ditional information.
Eligibility criteria
All randomized, placebo-controlled trials (RCTs) that evaluated the
eﬀects of pharmacological doses of ginger (Zingiber oﬃcinale) ad-
ministered per os to postoperative patients were included. All types of
reported outcomes were analysed. Trials that studied homeopathic
preparations of ginger and/or combinations of ginger with other
treatments were excluded. Studies without an explicit description of the
ginger extract used were also excluded. Since the composition, and
therefore the eﬀects of ginger essential oil are not comparable to those
of the crude drug or extracts, aromatherapy results were not included in
this meta-analysis. Abstracts, conference abstracts, case series, and case
reports were also excluded.
Study selection
The Mendeley 1.17.9 software package was used for record man-
agement. After removing duplicates and records without an abstract,
the remaining records were screened for eligibility on the basis of paper
title and abstract. The eligibility of the full texts of the remaining re-
cords was assessed by two reviewers (B.T., R.V.) independently.
Disagreement between reviewers was resolved by discussion or, if ne-
cessary, by consulting with a third reviewer (D.C.).
Data extraction and synthesis of the results
Data collection was executed following the PRISMA guidelines.
Study characteristics and results were extracted by two reviewers in-
dependently. Discrepancies in extracted data were resolved by discus-
sion.
The following data items were extracted from the included papers:
study design, sample size and characteristics of the patient population,
intervention details, type(s) of comparator(s), outcome measures and
overall results. Presence of postoperative nausea and/or vomiting,
rescue antiemetic drug demand, and nausea scales and scores (visual
analogue scale, verbal descriptive scale) were extracted as outcome
measures.
Risk of bias
The risk of bias was assessed using the Cochrane Collaboration tool,
which includes seven speciﬁc domains: random sequence generation,
allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selective
reporting and other scores of bias. Publication bias was assessed by
performing Egger's regression tests, and also by visual evaluation using
funnel plots. A signiﬁcant test result (p<0.1) indicated the existence of
publication bias (Egger et al., 1997). Disagreements in quality of studies
were resolved by discussion. Risk of bias summary table and ﬁgure
were generated by the RevMan 5 software (Higgins et al., 2011).
Statistical analyses
For binary data, the pooled natural logarithm of relative risk values
(logRR) and their 95% conﬁdence intervals (CI) were calculated to
assess the eﬃcacy of ginger on PONV. In case of visual analogue (VAS)
and verbal descriptive scales (VDS), standardized mean diﬀerences
(SMD) with 95% CIs were computed to compare mean data. A two-
Table 2
Outcomes of the RCTs included in the meta-analysis.
First author (year) Group Dose Sample size VAS (mean ± SE) VDS (mean ± SE) RER* PON** POV***
Montazeri et al. (2013) Ginger powder 1000 mg 81 3.13 ± 0.23 – – 73 –
Placebo 79 3.53 ± 0.23 – – 73 –
Nale et al. (2007) Fresh ginger 250 mg 20 – – – 0 3
Placebo 20 – – – 2 1
Apariman et al. (2006) Ginger powder 1500 mg 30 – – – – 7
Placebo 30 – – – – 14
Nanthakomon and Pongrojpaw 2006 Ginger powder 1000 mg 60 0.84 ± 0.24 – 11 29 17
60 1.41 ± 0.29 – 20 40 28
Pongrojpaw and Chiamchanya (2003) Ginger powder 1000 mg 40 0.68 ± 0.37 – 3 12 7
Placebo 40 1.40 ± 0.37 – 8 23 12
Eberhart et al. (2003) Ginger extract 100 mg 59 12 24 18
Ginger extract 200 mg 57 12 22 13
Placebo 59 13 20 11
Visalyaputra et al. (1998) Ginger powder 2000 mg 27 – 0.48 ± 0.19 – 6 7
Placebo 28 – 0.64 ± 0.20 – 9 10
Arfeen et al. (1995) Ginger powder 500 mg 36 – 0.94 ± 0.22 9 12 5
Ginger powder 1000 mg 36 – 1.08 ± 0.22 10 13 11
Placebo 36 – 0.86 ± 0.20 8 8 6
Phillips et al. (1993) Ginger powder 1000 mg 40 – 0.63 ± 0.12 6 19 4
40 – 1.23 ± 0.18 15 25 9
Bone et al. (1990) Ginger powder 1000 mg 20 – 0.35 ± 0.13 – 23 9
Placebo 20 – 0.96 ± 0.25 – 41 14
* Rescue antiemetic drug demand.
** Number of patients with postoperative nausea.
*** Number of patients with postoperative vomiting.
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tailed p<0.05 was considered statistically signiﬁcant.
Heterogeneity was tested both by performing the Cochran's Q test
and calculating the Higgins’ I2 indicator (Cochran, 1954; Higgins et al.,
2003). The Q statistics was computed as the weighted sum of individual
study eﬀects’ squared deviations from the pooled eﬀect, with the
weights being used in the pooling method; p-values were obtained by
comparing the test statistics with a chi-square with k-1 degrees of
freedom (where k was the number of studies). A p-value of less than
0.05 was considered to be suggestive of signiﬁcant heterogeneity. The I2
index corresponds to the percentage of total variability across studies
caused by heterogeneity. Based on Cochrane's handbook, a rough
classiﬁcation of the I2 index value is the following: low (0–40%),
moderate (30–60%), substantial (50–90%) and considerable hetero-
geneity (75–100%) (Higgins and Green, 2011). In each case, a ﬁxed-
eﬀects model (using the Mantel-Haenszel method) or a random-eﬀects
model (using the DerSimonian-Laird method) was employed, de-
pending on the magnitude of heterogeneity (Mantel and Haenszel,
1959; DerSimonian and Laird, 1986).
For outcomes with appropriate patient numbers, subgroup analyses
for the diﬀerent doses of ginger were conducted. The following sub-
groups were distinguished: 1000mg ginger,<1000mg
ginger,> 1000mg ginger, and all pharmacological doses of ginger
used. The results were presented as forest plots. All the statistical
analyses were performed using the Comprehensive Meta-Analysis
software (version 3, Biostat Inc., Englewood, NJ, USA).
Results
Literature search and study selection
Using the search terms ginger and nausea for the literature search of
EMBASE, PubMed, the Cochrane Central Register of Controlled Trials
and Web of Science databases, and removing duplicate results, the
search yielded a total of 835 potentially relevant reports. One addi-
tional report (Janngam, 2003) was identiﬁed through screening the
reference lists of the previous meta-analysis of this topic
(Chaiyakunapruk et al., 2006). The RCTs to be included in the meta-
analysis were selected according to the ﬂow chart presented below
(Fig. 1).
After screening titles and abstracts, 23 publications were retrieved
for full-text screening, of which 13 RCTs were also excluded: in six
studies ginger essence or aromatherapy mixtures were used (Lee and
Fig. 2. The eﬀect of ginger on reducing the severity of PONV. (A) The eﬀect of all pharmacological doses of ginger on VAS scores in a ﬁxed-eﬀects model (n=3). (B)
The eﬀect of 1000mg ginger on VDS scores in a random-eﬀects model (n=3). (C) The eﬀect of all pharmacological doses of ginger on VDS scores in a random-eﬀects
model (n=5).
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Shin, 2017; Kiberd et al., 2016; Adib-Hajbaghery and Hosseini, 2015;
Hosseini and Adib-Hajbaghery, 2015; Hunt et al., 2013; de Pradier,
2006), while in two RCTs the applied product or the applied extracts of
ginger were not suﬃciently speciﬁed (Seidi et al., 2017; Zeraati et al.,
2016). In the RCT conducted by Seidi et al. (2017) the posology was not
clear, suggesting that surgeries may have been carried out hours after
administering the ginger capsules . Kalavala et al. (2013) reported only
the incidence of intraoperative nausea and vomiting; therefore, this
study was also excluded. In another case, a homeopathic dose (1mg) of
ginger combined with ondansetron was used (Mandal et al., 2014), and
in one study ginger was applied in combination with dexamethasone
(Tavlan et al., 2006); therefore, the impact of ginger on nausea and
vomiting was not assessable in these studies. In case of one RCT, only
the abstract of a published article was available; therefore, we could not
assess the full-text article, thus this study was not included into the ﬁnal
analysis (Gülhaş et al., 2003). The study performed by Janngam was
not included because it was not published in a peer-reviewed journal.
Finally, ten placebo-controlled randomized trials including a total of
918 patients were included in the quantitative analysis (see Supple-
mentary Table S1) (Montazeri et al., 2013; Nale et al., 2007; Apariman
et al., 2006; Nanthakomon and Pongrojpaw, 2006; Pongrojpaw and
Chiamchanya, 2003; Eberhart et al., 2003; Visalyaputra et al., 1998;
Arfeen et al., 1995; Philips et al., 1993; Bone et al., 1990).
Risk of bias assessment
Each study was evaluated for potential biases using the Cochrane
Collaboration tool for assessing the risk of bias. For each domain, stu-
dies were judged to be at either high (red), unclear (yellow) or low
(green) risk of bias (see Supplementary Figs S1 and S2).
Three studies showed a low risk of randomization bias (Montazeri
et al., 2013; Apariman et al., 2006; Eberhart et al., 2003). In the re-
maining studies the method used for randomization was not mentioned;
therefore, these studies were judged to have an unclear risk of selection
bias. Studies which failed to describe the methods used for random
sequence generation, allocation or blinding were reckoned to have an
unclear risk of selection, performance and detection bias, respectively.
Two studies were judged as having a high risk of performance and
detection bias due to the lack of blinding (Apariman et al., 2006;
Visalyaputra et al., 1998). Bone et al. (1990) and Nale et al. (2007) did
not present all the results numerically in their publications. Therefore,
attrition bias for these studies remained unclear. All the studies showed
a low risk of reporting bias, and an unclear risk of other types of bias.
Publication bias was assessed by performing Egger's tests, and
funnel plots were utilized for visual assessment. They revealed no
missing publications either for trials investigating postoperative nausea
(see Supplementary Fig. S3) or those investigating postoperative vo-
miting (see Supplementary Fig. S4) (p=0.41 and p=0.39, respec-
tively).
Study characteristics
The included clinical trials were conducted in six diﬀerent countries
[Thailand (n=4), the UK (n=2), Iran (n=1), Germany (n=1), India
Fig. 3. The eﬀect of ginger on rescue antiemetic drug demand. (A) All pharmacological doses of ginger assessed combined in a ﬁxed-eﬀects model (n=7), (B) A dose
of 1000mg of ginger assessed in a random-eﬀects model (n=4), (C) A dose of<1000mg of ginger (n=3) assessed in a ﬁxed-eﬀects model.
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(n=1), and Australia (n=1)], from 1990 until 2013. Table 1. sum-
marizes the key characteristics for each study included. Sample sizes
ranged from 40 to 175 patients. Compared to the previous meta-ana-
lysis on this topic (Chaiyakunapruk et al., 2006), six other RCTs were
included in the present meta-analysis. The eﬀect of ginger was in-
vestigated mainly in connection with gynaecological surgeries: eight
trials were carried out in gynaecological surgical patient populations,
and six on laparoscopic surgery patients. The majority of the patients
(814/918) were female.
Only studies assessing suﬃciently characterized ginger products
and using pharmacological doses of ginger were included in our meta-
analysis. In nine studies powdered ginger, in one trial ginger's acetone
extract (drug-extract ratio 10–20:1), and in another study freshly
shaved ginger was applied (Table 1). Although it is highly re-
commended to provide a quantitative description of the investigated
natural product(s) studied, the quantitative analysis of these products
was not provided in any of the included RCTs. Therefore, the exact
chemical composition of the applied products remains unknown.
Outcomes
The incidence and the severity of PONV were characterized in
various ways in the included RCTs. To describe the severity of PONV, a
4-point verbal descriptive scale (VDS) and a visual analogue scale (VAS)
were used in four and three RCTs, respectively. These two scales are
commonly used in the evaluation of subjective symptoms (e.g. pain,
anxiety, nausea), and are based on verbal communication to the pa-
tients (Boogaerts et al., 2000). VAS and VDS scores were presented as
mean ± SE. If the severity of PONV was considered unbearable for the
patient, a rescue antiemetic drug was allowed to be taken to reduce the
symptoms. In ﬁve RCTs, the number of patients who requested a rescue
antiemetic drug was also recorded. However, the particular rescue
antiemetic was not speciﬁed in any of the RCTs. The number of patients
with nausea/vomiting was reported in several trials to indicate the
incidence of PONV; therefore, these outcomes were also collected. In
two studies, ginger was given repeatedly (Nale et al., 2007; Eberhart
et al., 2003); for these RCTs, only the results reported before the second
administration were considered in the statistical evaluation. The ex-
tracted outcomes are listed in Table 2.
Fig. 4. The eﬀect of ginger on postoperative nausea. (A) All pharmacological doses of ginger assessed combined in a random-eﬀects model (n=11), (B) A dose of
1000mg of ginger (n=6) assessed in a random-eﬀects model, (C) A dose of<1000mg of ginger (n=4) assessed in a ﬁxed-eﬀects model.
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Eﬃcacy of ginger in alleviating the severity of PONV
Altogether, seven trials assessed the eﬀects of ginger on the severity
of PONV. Three trials reported VAS and four reported VDS results.
Ginger was found to lower the VAS scores in the treated groups: it had a
signiﬁcant eﬀect on the VAS scores compared to placebo. According to
the ﬁxed-eﬀects model (Q=0.224, df= 2, p=0.894, I2=0%) the
pooled standardized mean diﬀerence (SMD) was −0.247 (favouring
ginger; lower limit of 95% CI [LL]:−0.455, upper limit of 95% CI [UL]:
−0.040, p-value: 0.019) (Fig. 2A).
The verbal descriptive scale (VDS) was used in four trials, two of
which tested two diﬀerent doses of ginger. Therefore, the eﬀect of
1000mg ginger and the impact of all pharmacological doses of ginger
(250–2000mg) were examined independently. Both analyses failed to
prove the eﬃcacy of ginger. For the 1000mg dose, a random-eﬀects
model was applied (Q=7.482, df= 2, p=0.024, I2=73.27%), and
the pooled SMD was−0.336 (favouring ginger; LL:−0.936, UL: 0.203,
p-value: 0.208) (Fig. 2B). When all the VDS results were analysed
Fig. 5. The eﬀect of ginger on postoperative vomiting. (A) All pharmacological doses of ginger assessed combined in a random-eﬀects model (n=11), (B) A dose of
1000mg of ginger assessed in a random-eﬀects model (n=5), (C) A dose of<1000mg assessed in a ﬁxed-eﬀects model (n=4), (D) A dose of>1000mg of ginger
assessed in a ﬁxed-eﬀects model (n=2).
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combined, the impact of ginger further diminished, as indicated by a
pooled SMD (using a random-eﬀects model [Q=9.571, df= 4,
p=0.048, I2=58.21%]) of −0.228 (favouring ginger; LL: −0.575,
UL: 0.119, p-value: 0.197) (Fig. 2C).
Rescue antiemetic drugs were given to patients in ﬁve trials, and
altogether, seven diﬀerent treatment arms were available. After ex-
amining all the results combined (group A), subgroup analyses were
performed for the 1000mg dose (group B), and for the<1000mg dose
of ginger (group C). Results of the analyses failed to show any diﬀer-
ence in rescue antiemetic drug demand for the diﬀerent doses of ginger
versus placebo. For all pharmacological doses, a ﬁxed-eﬀects model was
applied (Q=7.469, df= 6, p=0.280, I2=19.67%), and the pooled
natural logarithm of the relative risk (logRR) was=−0.269 (favouring
ginger; LL: −0.563; UL: 0.025; p-value: 0.072). In a random eﬀects
model (Q=4.686, df= 3, p=0.196, I2=35.98%) the logRR was
−0.515 (favouring ginger; LL: −1.042; UL: 0.012; p-value: 0.055) for
group B (Fig. 3B), while a ﬁxed-eﬀects model [Q=0.139, df= 2,
p=0.933, I2=0%] yielded a logRR of−0.016 for group C (favouring
ginger; LL: −0.440; UL: 0.408; p-value: 0.941) (Fig. 3C).
Impact of ginger on the incidence of PONV
The number of patients with postoperative nausea or vomiting were
provided in ten studies. Pharmacological doses of ginger
(100–2000mg) mitigated nausea symptoms compared to placebo, but
this eﬀect was not statistically signiﬁcant. The pooled logRR (using a
random-eﬀects model [Q=22.868, df= 10, p=0.011, I2=56.27%])
was −0.151 (favouring ginger; LL:−0.351; UL: 0.048; p-value: 0.137)
(Fig. 4A). Subgroup analyses were carried out to determine whether the
eﬀects of ginger were dose-dependent. The pooled logRR (using a
random-eﬀects model [Q=17.843, df= 5, p=0.003, I2=71.98%])
was −0.256 (favouring ginger; LL:−0.518; UL: 0.007; p-value: 0.056)
for the 1000mg dose subgroups combined (Fig. 4B). Results for the
trials assessing less than 1000mg of ginger were pooled in a ﬁxed-ef-
fects model (Q=1.763, df= 3, p=0.623, I2=0%), and in this case
the logRR was 0.178 (favouring placebo; LL: −0.129; UL: 0.485; p-
value: 0.256) (Fig. 4C). Thus, neither the 1000mg dose, nor doses less
than 1000mg had statistically signiﬁcant eﬀects the incidence of
postoperative nausea. However, there was a trend towards higher doses
being more eﬀective than lower doses of ginger in reducing the in-
cidence of postoperative nausea.
Ginger seemed to lower the incidence of postoperative vomiting, but
this eﬀect was not statistically signiﬁcant either: using a random-eﬀects
model (Q=15.779, df= 10, p=0.106, I2=36.62%) the pooled
logRR was −0.194 (favouring ginger; LL: −0.492; UL: 0.104; p-value:
0.203) (Fig. 5A). The eﬀects of ginger remained insigniﬁcant even after
conducting dose-based subgroup analyses. In the subgroup of 1000mg
of ginger, the logRR was −0.360 (favouring ginger; LL: −0.744; UL:
0.023; p-value: 0.065), using a random-eﬀects model (Q=5.831,
df= 4, p=0.212, I2=31.41%) (Fig. 5B). For doses less than 1000mg,
the pooled logRR was 0.303 (favouring placebo; LL:−0.130; UL: 0.737;
p-value: 0.171) in a ﬁxed-eﬀects model (Q=1.666, df= 3, p=0.644,
I2=0%) (Fig. 5C). For doses over 1000mg, the pooled logRR was
−0.520 (favouring ginger; LL:−1.071; UL: 0.031; p-value: 0.064) in a
ﬁxed-eﬀects model (Q=0.438, df= 1, p=0.508, I2=0%) (Fig. 5D).
Side eﬀects
Ginger has been safely used for thousands of years
(Srinivasan, 2017). In the literature, including the most recent RCTs, no
serious adverse events ascribed to ginger are reported. In three trials, no
patients reported any side eﬀects after taking ginger preparations
(Montazeri et al., 2013; Nale et al., 2007; Nanthakomon and
Pongrojpaw 2006). In three other studies, the incidence of side eﬀects
was not reported (Visalyaputra et al., 1998; Arfeen et al., 1995; Bone
et al., 1990). In another three studies, postoperative patients com-
plained about heartburn, diarrhoea, mouth irritation, itching, abdom-
inal discomfort, insomnia, respiratory discomfort, and ﬂu-like symp-
toms (Apariman et al., 2006; Pongrojpaw and Chiamchanya, 2003;
Eberhart et al., 2003). The reported side eﬀects were not signiﬁcantly
diﬀerent from those of placebo (Philips et al., 1993).
Discussion
Ginger has been used to ameliorate gastrointestinal disorders (e.g.
nausea, vomiting, diarrhoea, etc.) since ancient times (Sheikhi et al.,
2015). Nowadays, ginger is used as a complementary herbal medicine
for the treatment of postoperative nausea and vomiting (Shariﬁ-
Rad et al., 2017). The present meta-analysis was designed to synthesize
the available evidence for this use. Ten RCTs were identiﬁed in the
literature, which included nearly 1000 postoperative patients, and led
to mixed results, demonstrating either the superiority or non-super-
iority of ginger (100–2000mg) over placebo. Therefore, based on our
meta-analysis, the superiority of ginger over placebo in the treatment of
PONV is still uncertain. Based on VAS results ginger was demonstrated
to reduce the severity of PONV, but its eﬀect on VDS scores was not
signiﬁcant. On the other hand, the subgroup analyses of diﬀerent doses
of ginger suggest that it may reduce the incidence of postoperative
vomiting and nausea in a dose-dependent manner. However, its eﬀects
were not statistically signiﬁcant even at higher doses (≥1000mg).
Therefore, although ginger and ginger medicines are traditionally used
for the treatment of nausea and vomiting, the optimum dose of ginger
for preventing PONV is still unclear; our results suggest that it might
exceed 1000mg.
Compared to the previously published systematic review
(Chaiyakunapruk et al., 2006), our meta-analysis has many strengths.
Using explicit eligibility criteria, we excluded one trial which had been
included in the previous meta-analysis, because this trial was only
published in a master thesis, and not in a peer-reviewed journal
(Janngam 2003). In our meta-analysis all trials investigating pharma-
cological doses of ginger were analysed; therefore, two trials which had
been excluded from the previous systematic review were included here
(Arfeen et al., 1995; Eberhart et al., 2003). A comprehensive search
yielded four eligible trials (Montazeri et al., 2013; Nale et al., 2007;
Apariman et al.; 2006; Nanthakomon and Pongrojpaw 2006) that were
published after the previous meta-analysis was carried out
Table 3
The eﬀectiveness of diﬀerent dose ranges of ginger used in the RCTs included in the meta-analysis.
Dose Outcome
VAS VDS Rescue antiemetic drug demand Postoperative nausea Postoperative vomiting
<1000 mg Not tested* Not tested* Not superior** Not superior** Not superior**
1000 mg Superior Not superior** Not superior** Not superior** Not superior**
>1000 mg Not tested* Not tested* Not tested* Not tested* Not superior**
All pharmacological doses Superior Not superior** Not superior** Not superior** Not superior**
* Not tested due to the lack of studies.
** Not superior compared to placebo.
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(Chaiyakunapruk et al., 2006). In our meta-analysis only placebo-con-
trolled, randomized trials were included. Trials assessing poorly char-
acterized ginger extracts and trials with unclear posology were ex-
cluded (Zeraati et al., 2016; Seidi et al., 2017).
Limitations of this review are largely related to those of the primary
studies. Eﬃcacy of ginger products may vary depending on their
composition. Gingerols are thermally labile compounds, and may suﬀer
partial dehydration to form shogaols during drying and storage of
ginger (Shariﬁ-Rad et al., 2017). Further reduction of shogaols may
yield paradols. Therefore, the chemical composition of ginger pre-
parations may vary depending on the drying process and storage con-
ditions. Although crude drugs and well-characterized extracts were
used in all the included trial, the chemical composition of ginger may
have changed signiﬁcantly during processing. Therefore, the composi-
tions of the applied products could have diﬀered.
The eﬀectiveness of ginger was assessed in many diﬀerent ways, so
various outcomes were tested. Few publications reported the same
outcomes; therefore, the forest plots were relatively small. Publication
bias regarding the incidence of postoperative nausea and postoperative
vomiting was assessed both by the Egger's tests and visually (using
funnel plots), as the number of trials reporting the same outcomes was
too low to properly assess more funnel plots.
The eﬀects of ginger on the outcomes tested in RCTs are summar-
ized in Table 3. Subgroup analyses for the diﬀerent dose ranges of
ginger were carried out to reveal a potential dose-dependency of gin-
ger's eﬃcacy. However, for several outcomes the lack of clinical data
hindered the testing of the results in dose-based subgroups.
Conclusions
Although ginger is safe and is generally better tolerated than syn-
thetic medications for PONV, the scientiﬁc evidence supporting its use
as a herbal medicine for the treatment of PONV is still limited. Our
meta-analysis supports that ginger decreases the severity of PONV, and
suggests that at higher doses (≥1000mg) it may also reduce the in-
cidence of postoperative nausea and vomiting, and thus the demand for
a rescue antiemetic agent. According to literature data, higher doses of
ginger perform better in lowering the incidence of PONV, but the ad-
vantages of ginger use are most likely to be noticed upon the admin-
istration of doses exceeding 1000mg. If, as suggested by our results, the
favourable eﬀects of ginger on reducing the incidence of PONV is dose-
dependent, it can be stated that most of the studies did not use the
appropriate amount of ginger. There is a clear need for high-quality
trials of appropriate patient size, examining the eﬀects of higher doses
or standardized extracts of ginger and applying comparable endpoints
to assess the eﬃcacy of ginger with a lower risk of bias.
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